An interventional study of Hetrombopag in Delayed Platelet Engraftment, Neuroblastoma and Autologous Hematopoietic Stem Cell Transplantation, sponsored by Beijing Children's Hospital. Recruiting at 1 site in China. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by Beijing Children's Hospital · Not applicable, Interventional, and Prevention
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is:
625 studies on the registry are indexed under Neuroblastoma; 122 are open to participants now.
This study's planned enrollment of 30 is close to the median of 32 across 475 interventional studies indexed under Neuroblastoma.
Browse Neuroblastoma studies →Beijing Children's Hospital is the lead sponsor of 51 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Hetrombopag
Patients enrolled were administered Hetrombopag starting from +4d after transplantation on routine medication of recombinant human thrombopoietin injection (rhTPO). The starting dose of Hetrombopag is 2.5mg or 5mg, oral, once daily (starting at 5mg/d for body weight\>20kg; starting from 2.5mg/d for body weight ≤ 20kg). Adjust the dosage based on platelet count every two weeks, with a maximum dose of 7.5mg per day. Stop the medication after 6 weeks of continuous use or when PLT reaches 100 × 10\^9/L.
Accumulated platelet engraftment rate
Platelet engraftment is defined as a continuous 7-day PLT ≥ 20 × 10\^9/L without platelet infusion.
Time frame: From enrollment to 60 days post-transplant
Number of platelet transfusions
Time frame: From enrollment to 60 days post-transplant
Time to platelet engraftment
Time frame: From enrollment to 60 days post-transplant
progression-free survival (PFS)
The time from enrollment to the first occurrence of disease progression or death from any cause
Time frame: From enrollment to 60 days post-transplant
Adverse events
Any adverse events within 30 days of discontinuation
Time frame: From medication to 30 days after discontinuation
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Children's Hospital